PMID- 37038024
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230529
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Linking)
VI  - 17
IP  - 3
DP  - 2023 Jun
TI  - Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without 
      transarterial chemoembolization in unresectable hepatocellular carcinoma.
PG  - 753-764
LID - 10.1007/s12072-023-10502-3 [doi]
AB  - PURPOSE: To compare the clinical benefit and tolerability of triple therapy of 
      lenvatinib, programmed death 1 (PD-1) inhibitor, and transarterial 
      chemoembolization (TACE) versus dual therapy of lenvatinib and PD-1 inhibitor in 
      unresectable hepatocellular carcinoma (HCC) patients. METHODS: Between October 
      2018 and September 2021, patients with unresectable HCC who received triple 
      therapy of lenvatinib, PD-1 inhibitor, and TACE or dual therapy of lenvatinib and 
      PD-1 inhibitor participated in this study. The efficacy was evaluated by survival 
      and therapeutic response, and the tolerability was evaluated by the frequency and 
      severity of key adverse events (AEs). RESULTS: In total, 118 eligible patients 
      with unresectable HCC who received combination therapy were included in this 
      study. Among them, 60 patients received triple therapy of lenvatinib, PD-1 
      inhibitor, and TACE (L-P-T group), and 58 eligible patients received dual therapy 
      of lenvatinib and PD-1 inhibitor (L-P group). Patients who received triple 
      therapy had better overall survival (OS) [median, 29.0 vs. 17.8 months, p < 0.01] 
      and progression-free survival (PFS) [median, 16.2 vs. 10.2 months, p < 0.01] than 
      those who received dual therapy. The objective response rate (76.7 vs. 44.9%, 
      p < 0.01) and disease control rate (96.7 vs. 75.9%, p < 0.01) in the L-P-T group 
      were higher than in the L-P group, respectively. Multivariate analyses revealed 
      that the treatment option and BCLC stage were independent prognostic factors for 
      OS, while treatment option and tumor number were independent prognostic factors 
      for PFS. The incidence and severity of AEs in the L-P-T group were comparable to 
      those in the L-P group (any grade, 95.0 vs. 94.8%, p = 1.00; grade >/= 3, 30.0 vs. 
      27.6%, p = 0.93). CONCLUSION: Triple therapy of lenvatinib, PD-1 inhibitor, and 
      TACE may achieve more favorable survival benefits than dual therapy of lenvatinib 
      and PD-1 inhibitor in unresectable HCC patients with manageable safety profiles.
CI  - (c) 2023. Asian Pacific Association for the Study of the Liver.
FAU - Xin, Yujing
AU  - Xin Y
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Zhang, Xinyuan
AU  - Zhang X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Liu, Ning
AU  - Liu N
AD  - School of Software, Shandong University, Jinan, 250101, Shandong, China.
FAU - Peng, Gang
AU  - Peng G
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Huang, Xiaoyu
AU  - Huang X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Cao, Xiaojing
AU  - Cao X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Zhou, Xiang
AU  - Zhou X
AUID- ORCID: 0000-0003-0935-8175
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China. zhou.xiang@yeah.net.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
LA  - eng
GR  - ZR2022QF114/Key Technology Research and Development Program of Shandong/
PT  - Journal Article
DEP - 20230410
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Immune Checkpoint Inhibitors
MH  - *Chemoembolization, Therapeutic
MH  - *Liver Neoplasms/drug therapy
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - PD-1 inhibitor
OT  - Transarterial chemoembolization
EDAT- 2023/04/11 06:00
MHDA- 2023/05/29 06:42
CRDT- 2023/04/10 23:24
PHST- 2022/11/14 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/04/10 23:24 [entrez]
AID - 10.1007/s12072-023-10502-3 [pii]
AID - 10.1007/s12072-023-10502-3 [doi]
PST - ppublish
SO  - Hepatol Int. 2023 Jun;17(3):753-764. doi: 10.1007/s12072-023-10502-3. Epub 2023 
      Apr 10.